Clinical Trial Update: Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial in China evaluating rituximab with an anti-CD38 monoclonal antibody versus rituximab alone for primary immune thrombocytopenia; recruitme…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Anti-CD38 monoclonal antibody (CD38-directed monoclonal antibody)
• Rituximab (rituximab)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Immune Thrombocytopenia, Treatment | Phase 2 | Status: RECRUITING